Close X
my esmo
 
Username: Password:
Remember me!


Forgot your Password? Create an account

Use of the ESMO services is subject to the Terms & Conditions and constitutes your agreement to abide by these.

Close X
my esmo
 
Username: Password:
Remember me!


Forgot your Password? Create an account

Use of the ESMO services is subject to the Terms & Conditions and constitutes your agreement to abide by these.

ESMO FAMILY SITES
ESMO » EVENTS » BREAST 2012 - IMPAKT » PROGRAM

Program

 Highlights

  • New trends in pathology research. Session facilitating discussion between clinicians, scientists and pathologists, the latter often relegated backstage, despite their crucial role.

  • Updates on recent landmark translational aspects in breast cancer. Overviews of novel drugs and biomarkers still under development but close enough to be relevant for the clinic.

  • Biomarker approval and reimbursement policies (Satellite Symposium). Hot issues for those clinicians who would like to do their best but are not always allowed to.

  • Biomarker consensus and guidelines (New!). Consensus opinions about the clinical relevance of prognostic multigene signatures in daily practice and about defining medically useful molecular sub-classification of breast cancer. This IMPAKT first will generate published biomarker guidelines − to be built upon during subsequent conferences!

  • Triple negative breast cancer. Comprehensive overview of translational and basic research and its clinical implications for a breast cancer sub-type still lacking targeted treatments.

  • Lessons learned. What can we learn from clinical trial failures to optimize future drug development?

Program focus

The IMPAKT 2012 program has been developed around a fundamental concept: novel technologies and advances in drug development are having an enormous impact on how breast cancer patients are treated.

Keeping this in mind, the program offers two different but complementary perspectives:

  • the need for clinicians to keep pace with the rapidly growing body of knowledge about new molecular pathways, targets, biomarkers, drugs, genomic technologies at the same time that they update their skills to integrate and use such new technologies.

  • the need for basic researchers to understand and address clinical challenges to better direct their efforts in the laboratory.

CME accreditation

The program of this event will be:

  • Accredited with 24 ESMO-MORA category 1 points.
  • Accredited with 15 European CME credits by the ACOE (Accreditation Council for Oncology in Europe). ACOE accreditation has been endorsed by the Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). These credits are also recognized by the American Medical Association (AMA) as Physician’s Recognition Award (AMA PRA category 1 credits).

 

Publications

All abstracts will be published online as a supplement of the official ESMO journal, Annals of Oncology.

OncologyPro

Access to the highest quality scientific knowledge at a click. In addition to a wider range of scientific information  and news services, OncologyPRO provides access to materials developed by ESMO. Webcasts and reports from the Conference will be available at http://oncologypro.esmo.org/

ESMO designed OncologyPRO in partnership with Thomson Reuters specifically to foster the sharing of knowledge and best practice for both clinical practice and research. OncologyPRO offers ESMO members an unparalleled resource - integrating regularly updated oncology news, clinical research, biomarker and drug databases, practice guidelines and tools, clinical trial information, abstracts from more than 110 oncology-relevant journals and more, in a simple, searchable platform.

BACK TO TOP BACK TO TOP PRINT THIS PAGE PRINT THIS PAGE